

II. REMARKS**Restriction Requirement**

Claims 1-14 are pending. The Examiner has required restriction of the claims to one of the following groups under 35 U.S.C. §121:

I. Claims 1-7, drawn to a method of treating systemic lupus erythmatosus in a patient in need thereof comprising administering a humanized anti-CD11a antibody, classified in Class 424, subclass 133.1.

II. Claims 8-14, drawn to a method of treating multiple sclerosis in a patient in need thereof comprising administering a humanized anti-CD11a antibody, classified in Class 424, subclass 133.1.

Applicants elect without traverse to prosecute the invention of the Group I, claims 1-7.

Amendments to the specification and claims

By virtue of this amendment, claims 8-14 are canceled without prejudice to refiling continuing application(s) directed thereto. Upon entry of this amendment, claims 1-7 will be pending.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 07-0630 (Ref. Docket No. P1014R1C1D1C1).

Respectfully submitted,
GENENTECH, INC.

Date: December 19, 2005

By: Lee K. Tan
Lee K. Tan, Ph.D.
Reg. No. 39,447
Telephone: (650)225-4462